China biopharmaceutical: second generation highly selective P2X3 inhibitor approved clinical trial

IntoCare Zhang Hui: Ingenuity Forges Quality, Continuous Improvement Safeguards Lives

In 2024, nearly all medical enterprises are exploring overseas markets. This trend is driven by an anti-corruption wave within the medical industry, the demand for financing and initial public offerings, as well as challenges such as excess production capacity. Presently, venturing abroad has become an essential developmental path for medical device enterprises. Successfully entering foreign markets is not only a crucial means for the medical industry to achieve a second grow

China's First Modified New Drug of Docetaxel Successfully Went to the US

Saudi Arabia to Host the 2029 Asian Winter Games, Creating a Snowy Future in the Desert

Telefónica Plans to Sell Mexican Operations, Potentially Reshaping Latin America's Telecom

February 14, 2025 – Spanish telecom giant Telefónica has hired JPMorgan to oversee the sale of its Mexican operations, aiming to complete the transaction before its annual shareholders' meeting.

CTTQ, Ampsourcebio Ink Agreement on Cure for NASH, T2DM

There are more than 95 plus major players and more than 90 plus nonalcoholic steatohepatitis (NASH) pipeline therapies, but none of them has been approved for marketing. Who would survive the competition in the blue-ocean market for NASH?